Table 1.
Therapeutic agent | Manufacturer | Target | Proposed mode of action |
---|---|---|---|
BMS986036 | Bristol-Myers Squibb | Modulation of FGF21 metabolism | Improvement of hepatic lipid and glucose metabolism; anti-inflammatory |
Cenicriviroc | Tobira Therapeutics | CCR2 and CCR5 | Inhibition of CCR2- and CCR5-mediated monocyte/macrophage infiltration and inflammation |
Elafibranor | Genfit | Modulation of hepatic PPARα and PPARδ pathways | Stimulation of NEFA oxidation; improvement of lipid and glucose metabolism; prevention of inflammation |
Emricasan | Conatus Pharmaceuticals | Caspase pathways (pan-caspase inhibitor) | Inhibition of fibrosis by blocking caspase protease activation and apoptosis pathways |
GR-MD-02 | Galectin Therapeutics | Galectin-3 inhibitor | Prevention of inflammation and fibrosis |
Obeticholic acid | Intercept Pharmaceuticals | FXR agonist | Regulation of hepatic glucose and lipid metabolism |
Px-104 | Phenex Pharmaceuticals/ Gilead Sciences | FXR agonist | Regulation of hepatic glucose and lipid metabolism |
Simtuzumab | Gilead Sciences | LOXL2 enzyme activity | Inhibition of fibrosis by a LOXL2 monoclonal antibody |
Agents are listed in alphabetical order
FXR, Farnesoid X receptor; LOXL2, Lysyl oxidase-like 2